Check out these sales figures for AMGN's kidney disease anemia drugs:
<<Aranesp sales decreased 7 percent to $580 million in the first quarter of 2011 versus $627 million in the first quarter of 2010.......EPOGEN sales decreased 14 percent to $535 million in the first quarter of 2011 versus $623 million in the first quarter of 2010.........>>
So in the first 90 days of 2011, Aranesp sold $580 million.....EPOGEN sold $535 million.
Combined??? That is $1,115,000,000 billion in three months. Thats not a billion dollar drug "annually"....but a BILLION every 90 days! To treat anemia in kidney patients.
Wouldn't one think that AMGN might be interested in what these Japanese researchers saw in TB 4 fragment?. I know it's all early stage....but again, it was HUMAN plasma samples ....not mice... or petri dish stuff.
Add a little "drip" of Thymosin Beta to the dialysis machine...could it aid anemia??? You won't know until you try.
Therein lies the rub. We're stuck with Finklestein....RGN has no money...and RGN is at 18 cents...making it all but impossible to ever raise trials funds without destroying the company. Maybe that has been Cavazza's plan all along......pick up the pieces for nothing...literally.